Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 QT study of clascoterone 7.5% solution
NCT03665194Phase 1Completed
- Sponsor
- Cassiopea S.p.A.
- Start
- Jun 2018
- Primary completion
- Sep 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in androgenetic alopecia (AGA) comparing Clascoterone 7.5% with Placebo (2 arms). Primary endpoints: Pharmacokinetic parameters of Cortexolone 17α-propionate and metabolites at Day 6 and QT interval changes at Day 6. Started Jun 2018; status: completed.
02
Drugs
clascoterone
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on NCT03665194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03665194.